Furthermore, when proceeding towards subgroup analysis by grouping all patients of the combined cohorts into the four main tumor entities present in the manuscript (NSCLC n = 52, HCC n = 51, melanoma n = 11, other GI tumors n = 14), we could again demonstrate that higher values of soluble CD27 confer patients a worsened PFS and OS, as well as an impaired objective response, with significant differences in PFS and OS in NSCLC and HCC, OR in HCC and PFS in other GI tumors (Supp. This evidence concerns the gene CD27 and hepatocellular carcinoma.